Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Exelixis, Inc., EXEL
Summary: Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.
- Last Price: $22.09
- Price Change: $-0.29, -1.30%
- Yearly Gain: 35.02%
- Market Cap: $6.70B
- P/E Ratio: 33.98
Here are 3rd party ratings for EXEL:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Strong Buy, Top 31% (78 out of 252)
What is the sentiment on the street regarding Exelixis, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in EXEL or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on EXEL before you decide to make any investment.
Click here for chart >>
Madrigal Pharmaceuticals, Inc., MDGL
Summary: Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-' agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.
- Last Price: $251.03
- Price Change: $-6.35, -2.47%
- Yearly Gain: -3.71%
- Market Cap: $4.99B
- P/E Ratio: -12.56
Here are 3rd party ratings for MDGL:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 34% (86 out of 252)
What is the sentiment on the street regarding Madrigal Pharmaceuticals, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in MDGL or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on MDGL before you decide to make any investment.
Click here for chart >>
Dyne Therapeutics, Inc., DYN
Summary: Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.
- Last Price: $26.44
- Price Change: $-0.34, -1.27%
- Yearly Gain: 83.87%
- Market Cap: $2.14B
- P/E Ratio: -6.69
Here are 3rd party ratings for DYN:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 34% (86 out of 252)
What is the sentiment on the street regarding Dyne Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in DYN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on DYN before you decide to make any investment.
Click here for chart >>
Wave Life Sciences Ltd., WVE
Summary: WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.
- Last Price: $6.82
- Price Change: $0.53, 8.43%
- Yearly Gain: 60.85%
- Market Cap: $811.66M
- P/E Ratio: -8.12
Here are 3rd party ratings for WVE:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 30% (76 out of 252)
What is the sentiment on the street regarding Wave Life Sciences Ltd. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Negative
- Hedge Fund signal: High Risk
If you are interested in WVE or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on WVE before you decide to make any investment.
Click here for chart >>
Thanks for reading!